Sanofi’s Dupixent Is Bucking Lockdown Trend, For Now
Physicians Adopting Telemedicine At Speed
Its emerging flagship drug maintained rapid growth in Q1, but a longer lockdown will hit all competitors’ new prescriptions.
You may also be interested in...
While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.